Insulet Corporation
PODDInsulet is building a recurring, device-plus-consumables ecosystem around a simple idea, make insulin delivery wearable, automated, and easier to live with.
Because this is not just a medical device, it is a platform that could compound for decades if it keeps innovating.
Business Model
Devices plus services
It sells a controller and then recurring disposable pods that patients must reorder every few days.
Economic Engine
High cash generation
Gross margins of 71.6 percent and strong free cash flow conversion fuel reinvestment.
Long-Term Lens
Ecosystem durability
The key question is whether Omnipod remains a preferred platform in an increasingly automated diabetes market.
BinaPrint Snapshot
Style
Build
Fitness
Mixed
Updated Mar 8, 2026
On this page
Company Story
How do Insulet Corporation's business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A high-growth diabetes platform with real recurring revenue and strong margins, but long-term success hinges on staying ahead in a fast-moving, tech-driven medical arms race.”
What does Insulet Corporation actually do?
Insulet designs and sells a wearable insulin pump system called Omnipod for people with diabetes.
- Creates small, tubeless insulin pods worn on the body
- Provides a handheld or smartphone-based controller to manage insulin delivery
- Supports patients and providers with training and customer service
Why it matters
Chronic disease, recurring need
Diabetes requires daily insulin management, which creates long-lasting demand rather than one-time sales.
How does Insulet Corporation make money?
Insulet makes money by selling starter kits and then recurring disposable pods that patients must replace every few days.
- Initial sale of Omnipod system to new patients
- Ongoing pod refills that generate repeat revenue
- International expansion into new healthcare systems
Economic clue
71.6 percent gross margin
High gross margins suggest pricing power and room to fund research, marketing, and expansion.
Why do long-term investors keep Insulet Corporation on the radar?
Insulet sits at the intersection of a growing global diabetes population and the shift toward automated, wearable medical technology.
- Revenue has grown 25.3 percent per year on average over five years
- Margins are expanding as scale improves
- Free cash flow is 1.53 times net income, showing strong cash conversion
Investor takeaway
Platform, not product
If Omnipod becomes a long-term standard of care, recurring pod sales can compound for decades.
Based on company financial statements.
What Could Change The Story
- Proved it would move the profile toward Summit.
- Building would move the profile toward Flash.
Benchmark Comparison
How has Insulet Corporation performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$940.52
-5.9% total return
$1,753
+75.3% total return
$2,975
+197.5% total return
$1,393
+39.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| PODD | -5.9% | $940.52 |
| S&P 500 | +75.3% | $1,753 |
| Gold | +197.5% | $2,975 |
| Bitcoin | +39.3% | $1,393 |
From Mar 5, 2021 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Insulet Corporation
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to long-term growth in diabetes care and wearable health tech
- A company reinvesting heavily rather than paying dividends
- Recurring revenue tied to a chronic medical need
Be Careful If You Expect
- Stable earnings every single year, earnings fell 41.2 percent year-over-year
- A strong balance sheet profile, financial fitness is mixed
- High dividend income, the company pays none
What To Watch Over Time
- Adoption of Omnipod in international markets
- Sustained gross margin above 70 percent as competition increases
- Continued strong free cash flow relative to reported earnings
BinaPrint Position
Where does Insulet Corporation sit on the BinaPrint map right now?
Test whether business quality and financial profile match the company's stated narrative.
Advanced BinaPrint details
Open the axes, investor fit, and risk framing behind this profile.
Key Metrics
Which metrics matter most for Insulet Corporation right now?
Three durable business metrics that matter more than day-to-day price moves.
25.3% five-year average
93.6% five-year average
71.6% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 25.3% five-year average | Shows whether the business has been expanding fast enough to create more long-term value. |
| EPS Growth | 93.6% five-year average | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 71.6% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Insulet Corporation's fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
11.0% ROIC
71.6% gross margin
13.9% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 11.0% ROIC | The business is currently showing fair capital efficiency. |
| Profitability | 71.6% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 13.9% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Insulet Corporation?
Insulet Corporation currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Insulet Corporation?
Company-specific questions readers often ask about Insulet Corporation.
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Insulet makes and sells the Omnipod, a wearable insulin pump system that helps people with diabetes manage insulin without daily injections.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Recurring pod sales tied to a chronic disease create predictable demand, once a patient adopts Omnipod they reorder supplies regularly for years.
Global diabetes prevalence continues to rise, expanding the addressable market for automated insulin delivery over decades.
High gross margins of 71.6 percent provide room to invest in research and defend the product against competitors.
Five-year average revenue growth of 25.3 percent shows the product resonates with patients and providers, suggesting durable adoption momentum.
Bear case
What can break
A breakthrough in non-insulin diabetes treatments or a widely adopted cure could shrink the need for insulin pumps over 20 years.
Large medical device competitors could outspend Insulet in research and undercut pricing, compressing margins from the current 71.6 percent gross level.
Reimbursement changes by insurers or government programs could pressure pricing and slow adoption, especially internationally.
Technology failure or product recalls in a life-sustaining device could damage brand trust and trigger regulatory scrutiny.
Risk Radar
Key Risks
Where downside pressure can build.
Product concentration, the Omnipod platform represents the vast majority of revenue, so any disruption directly hits sales.
Margin pressure risk, gross margin of 71.6 percent could fall sharply if competitors trigger price competition.
Earnings volatility, earnings per share fell 41.2 percent year-over-year, showing sensitivity to investment cycles.
Pressure points
Concentration risk
Insulet is heavily concentrated around the Omnipod platform, which accounts for the overwhelming majority of revenue. This means product performance, regulatory approvals, and competitive positioning for a single franchise largely determine company outcomes.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $237.01
- Daily move
- -1.63%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.